These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 9403493)

  • 1. Ibuprofen does not suppress active multiple sclerosis lesions on gadolinium-enhanced MR images.
    Barkhof F; van Waesberghe JH; Uitdehaag BM; Polman CH
    Ann Neurol; 1997 Dec; 42(6):982. PubMed ID: 9403493
    [No Abstract]   [Full Text] [Related]  

  • 2. [Effect of weekly intramuscular interferon beta-1a on MRI lesions in patients with relapsing multiple sclerosis].
    Waubant E; Sloan R; Andersson PB; Goodkin D
    Rev Neurol (Paris); 1999; 155 Suppl 2():S20-3. PubMed ID: 10367321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.
    Minagar A; Alexander JS; Schwendimann RN; Kelley RE; Gonzalez-Toledo E; Jimenez JJ; Mauro L; Jy W; Smith SJ
    Arch Neurol; 2008 Feb; 65(2):199-204. PubMed ID: 18071030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a.
    Barkhof F; Rocca M; Francis G; Van Waesberghe JH; Uitdehaag BM; Hommes OR; Hartung HP; Durelli L; Edan G; Fernández O; Seeldrayers P; Sørensen P; Margrie S; Rovaris M; Comi G; Filippi M;
    Ann Neurol; 2003 Jun; 53(6):718-24. PubMed ID: 12783417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of interferon beta-1b on black holes in multiple sclerosis over a 6-year period with monthly evaluations.
    Bagnato F; Gupta S; Richert ND; Stone RD; Ohayon JM; Frank JA; McFarland HF
    Arch Neurol; 2005 Nov; 62(11):1684-8. PubMed ID: 16157739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of interferon beta in relapsing-remitting multiple sclerosis.
    Etheridge LJ; Beverley DW; Ferrie C; McManus E
    Arch Dis Child; 2004 Aug; 89(8):789-91. PubMed ID: 15269086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Seeing injectable MS therapies differently: they are more similar than different.
    Fox RJ; Arnold DL
    Neurology; 2009 Jun; 72(23):1972-3. PubMed ID: 19439722
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety of serial monthly administration of triple-dose gadopentetate dimeglumine in multiple sclerosis patients: preliminary results of the BECOME trial.
    Wolansky LJ; Haghighi MH; Sevdalis E; Cook SD; Sethi N; Liu J; Joseph G; Tulloch K; Cadavid D
    J Neuroimaging; 2005 Jul; 15(3):289-90. PubMed ID: 15951416
    [No Abstract]   [Full Text] [Related]  

  • 9. [A short history of beta-interferon therapy of multiple sclerosis].
    Stock G; Horowski R
    Med Klin (Munich); 2001 Sep; 96 Suppl 1():3-9. PubMed ID: 11603113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Combined treatment of multiple sclerosis. A case report].
    Fonseca A; Noda M; González I; Gámez O; Montoya A; Daudinot B
    Rev Neurol; 2001 May 16-31; 32(10):996-8. PubMed ID: 12809119
    [No Abstract]   [Full Text] [Related]  

  • 11. A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN.
    Patti F; Amato MP; Filippi M; Gallo P; Trojano M; Comi GC
    J Neurol Sci; 2004 Aug; 223(1):69-71. PubMed ID: 15261564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The role of interferon beta in the treatment of multiple sclerosis].
    Seeldrayers P
    Rev Med Brux; 1999 Sep; 20(4):A264-7. PubMed ID: 10523902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defining interferon beta response status in multiple sclerosis patients.
    Rudick RA; Lee JC; Simon J; Ransohoff RM; Fisher E
    Ann Neurol; 2004 Oct; 56(4):548-55. PubMed ID: 15389896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.
    Simon JH; Jacobs LD; Campion M; Wende K; Simonian N; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Alam JJ; Fischer JS; Goodkin DE; Granger CV; Lajaunie M; Martens-Davidson AL; Meyer M; Sheeder J; Choi K; Scherzinger AL; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Whitham RH
    Ann Neurol; 1998 Jan; 43(1):79-87. PubMed ID: 9450771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute pathological laughter.
    Okuda DT; Chyung AS; Chin CT; Waubant E
    Mov Disord; 2005 Oct; 20(10):1389-90. PubMed ID: 16007658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon beta 1a.
    Pozzilli C; Koudriavtseva T
    Baillieres Clin Neurol; 1997 Oct; 6(3):481-93. PubMed ID: 10101585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An exploratory study on interferon beta dose effect in reducing size of enhancing lesions in multiple sclerosis.
    Di Rezze S; Gupta S; Durastanti V; Millefiorini E; Pozzilli C; Bagnato F
    Mult Scler; 2007 Apr; 13(3):343-7. PubMed ID: 17439903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study.
    Pachner AR; Cadavid D; Wolansky L; Skurnick J
    Neurology; 2009 Nov; 73(18):1485-92. PubMed ID: 19884576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early treatment.
    Comi G
    Neurol Sci; 2006 Mar; 27 Suppl 1():S8-12. PubMed ID: 16708191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy with interferon beta-1b and azathioprine in secondary progressive multiple sclerosis. A two-year pilot study.
    Fernández O; Guerrero M; Mayorga C; Muñoz L; Leán A; Luque G; Hervás M; Fernández V; Capdevila A; de Ramón E
    J Neurol; 2002 Aug; 249(8):1058-62. PubMed ID: 12195454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.